0JBU Stock Chart & Stats
$13.07
-$0.04(-0.37%)
At close: 4:00 PM EDT
$13.07
-$0.04(-0.37%)
Day’s Range― - ―
52-Week Range$7.91 - $28.33
Previous CloseN/A
Volume24.00
Average Volume (3M)30.08K
Market Cap
$1.85B
Enterprise Value$1.89K
Total Cash (Recent Filing)$437.76M
Total Debt (Recent Filing)$73.41M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 05, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding140,126,700
10 Day Avg. Volume22,676
30 Day Avg. Volume30,080
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.90Price Target Upside59.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.2
Revenue Forecast (FY)$50.71M
Bulls Say, Bears Say
Bulls Say
Lonvo-z Phase III Efficacy And Regulatory ReadinessThe strong Phase III outcome validates lonvo-z as a potential one-time treatment for hereditary angioedema. Regulatory submission and commercial preparation create a credible path toward product revenue and diversify Intellia beyond collaborations.
Strong Liquidity And Low LeverageSubstantial liquidity and limited debt provide flexibility to fund late-stage trials, regulatory work and commercial launch preparations without immediate balance-sheet strain. The runway also reduces dependence on unfavorable near-term financing.
Promising CRISPR Pipeline Beyond Lonvo-zRapid, durable gene-editing activity in nex-z supports the broader value of Intellia’s in vivo CRISPR platform. A second advanced program could expand future commercial opportunities and reduce reliance on a single asset.
Bears Say
Persistent Losses And Worsening Cash BurnIntellia remains dependent on financing, partnerships or future product revenue because its development programs do not yet generate sufficient operating cash. Continued high spending could shorten the runway if launch timing or approvals are delayed.
Nex-z Liver Safety And HLA Subgroup RiskThe safety signal adds clinical and regulatory uncertainty to nex-z, potentially requiring screening, monitoring and patient exclusions. These measures may complicate trial execution, restrict the addressable population and increase development costs.
Unpredictable Collaboration Revenue And Rising Commercial CostsRevenue tied to partner activity is inherently lumpy and declined materially, while commercial preparation is increasing overhead before product sales begin. This combination can pressure results and leave Intellia reliant on uncertain milestones or financing.
Intellia Therapeutics News
0JBU FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest share price was $7.91 and its highest was $28.33 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.85B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 68 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.001.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Intellia Therapeutics dividends here
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -0.8.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 140,126,700 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 0.852%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in GB:0JBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.90 (59.91% Upside)
$20.90 (59.91% Upside)
Blogger Sentiment
Bullish
GB:0JBU Sentiment 70%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $135.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.64%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
0JBU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, concrete clinical progress — most notably the unequivocal Phase III success for lonvo‑z (87% attack reduction, 62% attack‑free and therapy‑free, favorable safety) and compelling nex‑z biological data (≈90% TTR knockdown, rapid and durable) — alongside active regulatory and commercial preparations. Financially, the company strengthened its cash position with a ~$195M financing and maintains a runway into at least 2028, although collaboration revenue declined and G&A rose as commercial build‑out continues. The primary concern is a nex‑z liver enzyme safety signal and the identification of an HLA C*05:01 subgroup (~12% of samples) associated with higher Grade 3+ transaminase events; the company has implemented mitigation, added HLA typing to protocols, and is engaging regulators. Overall, the positive clinical milestones and clear mitigation plan for the safety finding outweigh the operational and financial headwinds discussed.View all GB:0JBU earnings summaries0JBU Revenue Breakdown
100.00% Collaboration revenue
0JBU Stock 12 Month Forecast
Average Price Target
$20.90
▲(59.91% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―